Related Experiment Video
Updated: Jul 6, 2026

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
Published on: September 16, 2021
Oral contraceptives: mechanism of action, dosing, safety, and efficacy
1University of Pennsylvania School of Medicine, Philadelphia, USA.
Abstract:
The most widely used form of hormonal contraception is the combination oral contraceptive (OC). Combination OCs can be monophasic, providing the same dose of estrogen and progestin daily, or multiphasic, offering varying doses of hormones throughout a 21- or 28-day cycle. The objective of OCs is to suppress ovulation by manipulating events throughout the ovulatory cycle to prevent pregnancy. The progestin and estrogen components of OCs suppress the mid-cycle surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The overall effect is to decidualize the endometrial bed and suppress mitotic activity. Initial formulations of OCs in the 1960s attempted to mimic the natural cycle; however, providing high doses of estrogen rather than lower doses of combined estrogen and progestin resulted in greater risk of serious adverse events. Today, OCs provide far lower levels of estrogen and progestin. The availability of formulations with drospirenone, a unique progestin pharmacokinetically similar to progestin and similar in structure to spironolactone, should widen usage of OCs. Although OCs are still associated with increased risk in certain patients and are contraindicated in others, they remain effective but require diligent usage.
Related Concept Videos
Birth Control Methods
Intrauterine Drug Delivery Systems
Dosage Interval and Administration Route: Determination Methods
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Oral Drug Delivery Systems: Continuous-Release Systems
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
